The goals of Simmons Comprehensive Cancer Center (SCCC) Tissue Management Shared Resource (TMSR) are to facilitate the storage and distribution of comprehensively annotated, high-quality biospecimens and their derivatives and to provide professional and technical pathology services to investigators and collaborators within and outside of SCCC. Under the leadership of Adam Yopp, MD, the TMSR delivers basic histomorphological evaluation of human tumors and human tumor grafts in mice, as well as basic and advanced immunohistochemistry (IHC) services, creates custom tissue microarrays (TMA), and provides whole slide imaging and image analysis. In addition, the TMSR offers unique cancer-tissue derivatives such as primary cancer cell cultures and cell lines, cryopreserved tissues, DNA, and RNA. The TMSR currently has greater than 37,000 fresh frozen tissues and 42,000 formalin-fixed tissues, as well as clinically annotated TMAs with paired tumor and normal tissue from the following malignancies: breast, hepatocellular carcinoma, colon, lung, melanoma, gastric, and pancreas. In addition, the TMSR currently has greater than 42,000 serum and plasma blood samples and 8,000 buffy coat samples. Samples are listed in an annotated and searchable database that is available to SCCC members through the intranet. The TMSR provides routine quality controls for all prospectively consented collected specimens. The TMSR has had significant utilization, with greater than 3,500 samples having been distributed to investigators internally and externally in 2019. The TMSR promotes flourishing collaborations among SCCC investigators, investigators from other National Cancer Institute (NCI)- designated Comprehensive Cancer Centers, and other investigators in academia and industry. The services of the TMSR were utilized by 78 investigators across five SCCC Research Programs in 2019, providing key data and insights to support the success of NCI-funded research grants, including the lung and kidney cancer SPORE grants and 115 peer-reviewed publications, with work published in high-impact journals such as JCI, Cancer Discovery, Science Signaling, Science Immunology, Nature, and Nature Medicine. Over the current cycle, the TMSR had over a 100% increase in its usage due to rapid response to investigator needs and SCCC priorities.